Company Overview
In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications.
Fab’entech is a privately owned pharmaceutical company headquartered in Lyon (France) and created in 2009. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions to address bioterrorism threats & emerging infectious diseases, but also intoxications & severe infectious diseases.
Fab’entech is a privately owned pharmaceutical company headquartered in Lyon (France) and created in 2009. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions to address bioterrorism threats & emerging infectious diseases, but also intoxications & severe infectious diseases.
Immunotherapies to address situations of emergency
After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 2 products: a candidate targeting Ebola virus having been identified by WHO as the unique therapeutic solution in Europe in 2014, and an antidote candidate in the field of bioterrorism in collaboration with the French army. Fab’entech’s pipeline will be reinforced in the next few months with new antidote candidates addressing bioterrorism threats and intoxications.
Fab’entech is seeking investors to complete a fundraising round by Q4 2017. It is also looking for industrial partners to co-develop polyclonal immunotherapies in additional indications of emergency, preferably nosocomial infectious diseases.
Board
- Albert SAPORTA: President
- Frédéric HAMMEL: Independent
- Frank LESCURE: Auriga Partners
- Gwenaël HAMON: Kreaxi
- Guillaume HEMMERLE: Sigma Gestion
MANAGEMENT TEAM
- Bertrand LEPINE: CEO & Founder
- Charlotte REYNAUD DESREUX: Managing Director & Head of Pharmaceutical Affairs
- Cécile HERBRETEAU DELALE: Head of Research & Development
- Ludovic NGUYEN: Head of Industrial Operations
- Raphaël METROP: Head of Corporate Business Development
PARTNERS
